<DOC>
	<DOCNO>NCT00232297</DOCNO>
	<brief_summary>Primary objective : - ass efficacy SSR149744C prevention ventricular arrhythmia-triggered ICD intervention . Secondary objective : - ass versus placebo tolerability different dose regimen SSR149744C select population . - document SSR149744C plasma level study .</brief_summary>
	<brief_title>Double Blind Placebo Controlled Dose Ranging Study Efficacy Safety SSR149744c 100 300 mg Prevention ventrICular ARrhythmia-triggered Icd interventiOnS</brief_title>
	<detailed_description />
	<mesh_term>Tachycardia</mesh_term>
	<mesh_term>Ventricular Fibrillation</mesh_term>
	<mesh_term>Tachycardia , Ventricular</mesh_term>
	<criteria>Patient ICD implant previous year document spontaneous lifethreatening ventricular arrhythmia OR implant ICD least one appropriate ICD therapy ( shock antitachycardia pace ) ventricular tachycardia ventricular fibrillation previous year . Left ventricular ejection fraction measure 2Dechocardiography must document less 40 % last 6 month . MAIN CRITERIA ( nonexhaustive list ) : Women childbearing potential without adequate birthcontrol , Pregnant Women , Breastfeeding woman , condition increase risk severe antiarrhythmic drug side effect , severe associate condition .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Tachycardia , Ventricular</keyword>
	<keyword>Ventricular Fibrillation</keyword>
	<keyword>Defibrillators Implantable</keyword>
	<keyword>Arrhythmia</keyword>
	<keyword>Anti-arrhythmia agent</keyword>
</DOC>